PHARMACOKINETICS OF PROPHYLACTIC AND THERAPEUTIC FLUCONAZOLE IN PRETERM NEONATES

1A Engbers*, 2RB Flint, 1SM Voeller, 1KM Reiss, 3KD Liem, 4PL Degrasevve, 7P Andriasen, 8IWC Afflennaz, 6SHP Simons, 1CA Knibbe, 8RB Brüggemann, 5Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden; 2Department of Paediatrics, Division of Neonatology, Erasmus MC – Sophia Children’s Hospital; 3Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam; 4BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden; 5Department of Neonatology, Radboud University Medical Center, Nijmegen; 6Department of Paediatrics, Division of Neonatology, Maastricht University Medical Center, Maastricht; 7Department of Neonatology, Maxima Medical Center, Veldhoven; 8Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen; 9Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein; 10Department of Hospital Pharmacy, Radboud University, Nijmegen, The Netherlands

Introduction Fluconazole is a first choice drug for neonatal cerebral candidiasis and for prevention of candidemia/invasive candidiasis in neonates. Selection of the optimal neonatal dose is difficult and requires solid multiple dose pharmacokinetic (PK) research to guide dosing decisions. We performed a pharmacokinetic study in preterm neonates who received fluconazole prophylactically or as treatment.

Methods Preterm neonates received fluconazole according to local protocol for either prophylaxis or treatment in 5 different hospitals. Samples were collected on multiple occasions with an opportunistic sampling scheme. Patient characteristics were bodyweight, birthweight, postnatal age (PNA), gestational age (GA), postmenstrual age, gender and weight for age. Population PK modelling was performed using NONMEM V7.3.

Results In 44 preterm neonates (median (range) GA 25.3 (24.0–31.3) weeks), 153 plasma samples were collected. Median PNA at treatment initiation was 1 (0–59) day, treatment duration 11 (2–67) days and median PNA during treatment 15 (4–60) days. A one-compartment model described the data best, with an estimated clearance (CL) for a neonate of 0.84 kg and PNA of 15 days of 0.0147 L/h (RSE 4.3%, nshrinkage for Tlag and F were low, however nshrinkage for ka was 0.9999).

Conclusion This is the first known modelling of gentamicin delivery kinetics. The studies all had high nshrinkage for ka, therefore the individual estimates of ka may be unreliable. Further studies with a higher number of replicates would provide more favourable data for estimating Ka.

REFERENCE


Disclosure(s) No conflict of interest declared. Funding for research via the Freemasons Society of New Zealand.

DRUG DELIVERY KINETICS OF INTRAVENOUS GENTAMICIN IN A POPULATION OF NEONATES

1G Salsa*, 2N Medillcot, 3D Reith. Women’s and Children’s Health; 2New Zealand’s National School of Pharmacy, University of Otago, Dunedin, New Zealand

Background Gentamicin is commonly used in the NICU setting and is often administered via long lines, which increases variability in the rate of administration. We aimed to model drug delivery pharmacokinetic parameters for intravenous gentamicin administered via umbilical venous catheters (UVCs).

Methods Data was modelled from infusion simulations of gentamicin delivery using UVCs with a background flow rate of 0.5 ml/h. Different combinations of dose (2 mg, 5 mg) were given by bolus injection over 3–5 minutes, followed by a normal saline flush (1 ml, 2 ml). Gentamicin levels were measured at 5 minute intervals over an hour via high pressure liquid chromatography.

Phoenix Certara (version 8.1) was used for modelling. An extravascular model with clearance removal was used to predict parameters: absorption constant (Ka), time lag (Tlag), and bioavailability (F). F was used to enable an estimate of the variability in dose administered. Different error models were tested to ascertain which best described the data.

Results An extravascular one compartment model with first order absorption and additive error best described the data. Estimates for the model with a 2 mg dose and 1 ml flush were Ka 0.34 L/min, Tlag 1.28 min, F 0.97, standard deviation (stdev) 0.14. For 2 mg, 2 ml flush, estimates were Ka 0.86 L/min, Tlag 3.01 min, F 0.87, stdev 0.01. For 5 mg, 1 ml flush, estimates were Ka 0.48 L/min, Tlag 3.13 min, F 1.03, stdev 0.12. For 5 mg, 2 ml flush, estimates were Ka 0.83 L/min, Tlag 3.29 min, F 1.09, stdev 0.02. For each model epsshrinkage and nshrinkage for Tlag and F were low, however nshrinkage for ka was 0.9999.

Conclusion This is the first known pharmacokinetic study on fluconazole in preterm neonates, CL was influenced by both bodyweight and PNA while Vd was influenced by bodyweight only. These findings imply that initial dosing of fluconazole in preterm neonates should be based on bodyweight and that an increase of the dose with 32% during the first week and with 47% during the first month of life could be necessary because of increasing clearance with PNA.

Disclosure(s) Nothing to disclose

EFFECT OF HEMODIALYSIS DOSE (SPK/T/W) ON SURVIVAL IN PATIENTS ON MAINTENANCE HEMODIALYSIS SINCE CHILDHOOD – A RETROSPECTIVE ANALYSIS

1TV Gotta*, 3VA Atkinson, 2O Marsenic, 3M Pfister. 1Pediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel (UKBB); 2Hospital Pharmacy, University Hospital Basel; 3Pediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel (UKBB), Basel; 4Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland; 5Pediatric Nephrology, Yale University School of Medicine, New Haven, CT, USA

Background Hemodialysis (HD) prescription signficantly differs between pediatric and adult patients on maintenance HD, resulting in greater difference between prescribed and delivered HD dose.1,2 HD dose targets have formally not been evaluated for children, hence targets are mainly derived from adults (spKsv >1.4; sp: single-pool model of urea distribution, Ks: urea clearance, t: duration of HD session, V: urea distribution volume). This analysis aimed to evaluate the relationship between delivered dialysis dose and survival in a large cohort of patients having started HD therapy in childhood.

Disclosure(s) Nothing to disclose

References


Disclosure(s) No conflict of interest declared. Funding for research via the Freemasons Society of New Zealand.